Diabetic Retinopathy

The trial will be evaluating AXPAXLI dosed every 6 months vs aflibercept (2 mg) dosed every 8 weeks in treatment-naive patients with wet AMD.

Regeneron faces another FDA setback for Eylea HD due to manufacturing issues, but plans for new facilities signal future production improvements.

A recent study uncovers a novel biomarker for retinal vascular diseases, highlighting the significance of intermittent capillary perfusion in monitoring treatment efficacy.

The procedure showed positive effects on the electroretinography (ERG) (b-wave, oscillatory potentials), optomotor response, and contrast sensitivity in actively treated eyes compared with controls.

Eydenzelt is Celltrion's first FDA-approved biologic product in ophthalmology.

Biomarkers and fine-tuned staging are key to progress in improving retinal care, according to Fanka Gilevska, MD, PhD.

Justis Ehlers discusses promising results from the HELIOS trial, revealing a novel treatment for diabetic retinopathy that may reduce treatment frequency.

The country has a goal of ensuring that more than 95% of patients with diabetes receive timely retinal examinations.

Optain Health secures $26 million in Series A funding to enhance AI-driven retinal disease detection and expand its technology.

A study reveals similar risks of sight-threatening diabetic retinopathy in pregnant women with type 1 diabetes compared with nonpregnant controls.

The committee will work to help the organization increase awareness and early identification of diabetes-related eye diseases and improve access to eye care treatment, policy development, research, and surveillance.

Kriya is developing gene therapies targeting chronic diseases such as geographic atrophy, trigeminal neuralgia, and type 1 diabetes.

Research reveals that GLP-1 medications, including semaglutide, do not increase diabetic retinopathy risks, offering reassurance for patients and prescribers.

A new study highlights the effectiveness of ERG/pupillometry in predicting diabetic retinopathy progression, surpassing traditional imaging methods.

The agreement is for a planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR).

GLP-1 therapies could impact long-term outcomes in diabetic retinopathy.

REGENXBIO initiates a pivotal trial for surabgene lomparvovec, aiming to transform diabetic retinopathy treatment and improve patient outcomes.

Avant Technologies and Ainnova Tech refine clinical trial protocol for Vision AI platform, aiming for FDA 510(k) approval to enhance diabetic retinopathy detection.

Justis Ehlers, MD, FASRS, presented "PER-001, a Long-acting Endothelin Antagonist Intravitreal Implant, Improved Structure and Visual Function in Patients With Diabetic Retinopathy," during the 2025 ASRS meeting held in Long Beach, California.

Topcon Healthcare enhances its connected care model by acquiring IRIS, integrating AI for improved diabetic eye disease screening and patient coordination.

New clinical trials reveal PER-001 as a new treatment for glaucoma and diabetic retinopathy, showing significant vision improvements and safety.

Breye Therapeutics advances danegaptide, a novel oral therapy for non-proliferative diabetic retinopathy, showing promise in early clinical trials.

Innovative assistive devices empower patients with central vision loss to regain independence and enhance daily activities, transforming their quality of life.

Ainnova has collaborated with leading pharmacies to offer free diabetic retinopathy screenings to patients with diabetes.